We are pleased to share an exciting update on Dr. Diane Reidy’s project, “Personalized Medicine for Neuroendocrine Tumor Patients.” In particular, Dr. Reidy’s goals are to study patient tumor samples to develop biomarkers to predict patient response to targeted therapies. This will help classify pancreatic neuroendocrine tumor (pNET) patients for treatment with targeted therapies or chemotherapy. This project has been funded in part by NETRF’s Cycle for Survival Team. Since 2012, over $300,000 has been raised by Cycle for Survival to support this important work.
The project is still ongoing but has already made important advances. In particular, they have:
- Identified a new class of mutations among patients with pNETs and observed correlation between these patients and a good response to chemotherapy.
- Identified mutations among patients with pNETs similar to those found previously among patients with ileal carcinoid tumors that suggest a new treatment strategy. They plan to open a clinical trial to test this new treatment strategy in cooperation with other institutions in 2016.
- Identified mutations in MEN1, Daxx and ATRX among patients with pNETs similar to those previously identified by other NETRF researchers among patients with pNETs.
They still have important work to do in order to accrue more patients to the study and to find more correlations between patient mutational status and response to therapies. Read more about Dr. Reidy’s work on the Cycle for Survival page.
We need your continued support of our Cycle for Survival team to keep this important work going. Please consider signing up or joining today!